1
|
Rodriguez-Pinilla SM, Domingo-Domenech E, Climent F, Sanchez J, Perez Seoane C, Lopez Jimenez J, Garcia-Cosio M, Caballero D, Blanco Muñez OJ, Carpio C, Castellvi J, Martinez Pozo A, Gonzalez Farre B, Bendaña A, Aliste C, Gonzalez AJ, Gonzalez de Villambrosia S, Piris MA, Gomez Codina J, Mayordomo-Aranda E, Navarro B, Bellas C, Rodriguez G, Borrero JJ, Ruiz-Zorrilla A, Grande M, Montoto C, Cordoba R. Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study. Br J Haematol 2020; 192:82-99. [PMID: 32426847 PMCID: PMC7818499 DOI: 10.1111/bjh.16741] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Accepted: 04/21/2020] [Indexed: 12/18/2022]
Abstract
We investigated the clinicopathological features and prognostic factors of patients with peripheral T‐cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the International Prognostic Index and the Intergruppo Italiano Linfomi system, treatments, and clinical outcomes were examined. A sizeable proportion of 175 patients had a history of immune‐related disorders (autoimmune 16%, viral infections 17%, chemo/radiotherapy‐treated carcinomas 19%). The median progression‐free survival (PFS) and overall survival (OS) were 7·9 and 15·8 months, respectively. Prognostic indices influenced PFS and OS, with a higher number of adverse factors resulting in shorter survival (P < 0·001). Complete response (CR) to treatment was associated with better PFS (62·6 vs. 4 months; P < 0·001) and longer OS (67·0 vs. 7·3 months; P < 0·001) compared to no CR. CD30 was expressed across all subtypes; >15% of cells were positive in anaplastic lymphoma kinase‐positive and ‐negative anaplastic large‐cell lymphoma and extranodal natural killer PTCL groups. We observed PTCL distribution across subtypes based on haematopathological re‐evaluation. Poor prognosis, effect of specific prognostic indices, relevance of histopathological sub‐classification, and response level to first‐line treatment on outcomes were confirmed. Immune disorders amongst patients require further examination involving genetic studies and identification of associated immunosuppressive factors.
Collapse
Affiliation(s)
| | - Eva Domingo-Domenech
- Hematology Department, Institut Català d'Oncologia L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain
| | - Fina Climent
- Pathology Department, Hospital Universitari de Bellvitge. IDIBELL, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain
| | - Joaquin Sanchez
- Hematology Department and Pathology Department, Hospital Universitario Reina Sofía, Cordoba, Spain
| | - Carlos Perez Seoane
- Hematology Department and Pathology Department, Hospital Universitario Reina Sofía, Cordoba, Spain
| | | | - Monica Garcia-Cosio
- Anatomical Pathology Department, Hospital Universitario Ramón y Cajal, Madrid, CIBERONC, Madrid, Spain
| | - Dolores Caballero
- Hematology Department, Hospitalario Universitario de Salamanca (HUS/IBSAL) and CIBERONC, Salamanca, Spain
| | | | - Cecilia Carpio
- Hematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Josep Castellvi
- Pathology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Antonio Martinez Pozo
- Pathology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Universitat de Barcelona, Barcelona, Spain
| | - Blanca Gonzalez Farre
- Hematopathology Unit, Hospital Clínic Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) CIBERONC Universitat de Barcelona, Barcelona, Spain
| | - Angeles Bendaña
- Hematology Department, Complexo Hospitalario Universitario de Santiago de Compostela, La Coruña,, Spain
| | - Carlos Aliste
- Hematology Department, Complexo Hospitalario Universitario de Santiago de Compostela, La Coruña,, Spain
| | - Ana Julia Gonzalez
- Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | - Miguel A Piris
- Hospital Universitario Fundación Jiménez Díaz, Madrid, CIBERONC, Madrid, Spain
| | - Jose Gomez Codina
- Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | | | - Belen Navarro
- Hematology Department, Hospital Universitario Puerta de Hierro, Madrid, CIBERONC, Madrid, Spain
| | - Carmen Bellas
- Pathology Department, Hospital Universitario Puerta de Hierro, Madrid, CIBERONC, Madrid, Spain
| | - Guillermo Rodriguez
- Anatomical Pathology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/Universidad de Sevilla, Sevilla, Spain
| | - Juan Jose Borrero
- Anatomical Pathology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/Universidad de Sevilla, Sevilla, Spain
| | | | - Marta Grande
- Medical Department, Takeda Farmacéutica España S.A, Madrid, Spain
| | - Carmen Montoto
- Medical Department, Takeda Farmacéutica España S.A, Madrid, Spain
| | - Raul Cordoba
- Hematology Department, Fundación Jiménez Díaz, Madrid, CIBERONC, Madrid, Spain
| |
Collapse
|